Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 5,607Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 9Fampyra

PharmaCompass

01

Brand Name : Fampyra

Fampridine

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Fampyra

arrow
2024 ACI Convention
Not Confirmed

Fampridine

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 103

2019 Revenue in Millions : 97

Growth (%) : 6

blank

02

Brand Name : Fampyra

Fampridine

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Fampyra

arrow
2024 ACI Convention
Not Confirmed

Fampridine

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 105

2020 Revenue in Millions : 103

Growth (%) : 2

blank

03

Brand Name : Fampyra

Fampridine

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Fampyra

arrow
2024 ACI Convention
Not Confirmed

Fampridine

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 97

2021 Revenue in Millions : 105

Growth (%) : -8

blank

04

Brand Name : Fampyra

Fampridine

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Fampyra

arrow
2024 ACI Convention
Not Confirmed

Fampridine

Main Therapeutic Indication : Neurology

Currency : USD

2023 Revenue in Millions : 91

2022 Revenue in Millions : 97

Growth (%) : -6

blank

05

Brand Name : Fampyra

Fampridine

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Fampyra

arrow
2024 ACI Convention
Not Confirmed

Fampridine

Main Therapeutic Indication : Neuroscience and Mental Health

Currency : USD

2015 Revenue in Millions : 80

2014 Revenue in Millions : 90

Growth (%) : 13%

blank

06

Brand Name : Fampyra

Fampridine

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Fampyra

arrow
2024 ACI Convention
Not Confirmed

Fampridine

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2018 Revenue in Millions : 93

2017 Revenue in Millions : 92

Growth (%) : 1%

blank

07

Brand Name : Fampyra

Fampridine

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Fampyra

arrow
2024 ACI Convention
Not Confirmed

Fampridine

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2017 Revenue in Millions : 92

2016 Revenue in Millions : 85

Growth (%) : 8

blank

08

Brand Name : Fampyra

Fampridine

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Fampyra

arrow
2024 ACI Convention
Not Confirmed

Fampridine

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2016 Revenue in Millions : 85

2015 Revenue in Millions : 90

Growth (%) : -6

blank

09

Brand Name : Fampyra

Fampridine

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Fampyra

arrow
2024 ACI Convention
Not Confirmed

Fampridine

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2019 Revenue in Millions : 97

2018 Revenue in Millions : 93

Growth (%) : 5

blank